Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aerovate Therapeutics stock

Learn how to easily invest in Aerovate Therapeutics stock.

Aerovate Therapeutics Inc is a biotechnology business based in the US. Aerovate Therapeutics shares (AVTE) are listed on the NASDAQ and all prices are listed in US Dollars. Aerovate Therapeutics employs 25 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Aerovate Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AVTE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Aerovate Therapeutics stock price (NASDAQ: AVTE)

Use our graph to track the performance of AVTE stocks over time.

Aerovate Therapeutics shares at a glance

Information last updated 2022-10-03.
Latest market close$16.68
52-week range$7.74 - $27.83
50-day moving average $19.77
200-day moving average $14.41
Wall St. target price$26.33
PE ratio 0.5273
Dividend yield $0 (0%)
Earnings per share (TTM) $30.19

Buy Aerovate Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aerovate Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aerovate Therapeutics price performance over time

Historical closes compared with the close of $16.68 from 2022-10-04

1 week (2022-09-29) 6.11%
1 month (2022-09-06) -6.29%
3 months (2022-07-06) 8.24%
6 months (2022-04-06) 2.77%
1 year (2021-10-06) -12.26%
2 years (2020-10-02) N/A
3 years (2019-10-02) N/A
5 years (2017-10-02) N/A

Is Aerovate Therapeutics stock undervalued or overvalued?

Valuing Aerovate Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aerovate Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Aerovate Therapeutics's P/E ratio

Aerovate Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Aerovate Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Aerovate Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    Aerovate Therapeutics financials

    Gross profit TTM $0
    Return on assets TTM -21.61%
    Return on equity TTM -35.65%
    Profit margin 0%
    Book value $6.19
    Market capitalisation $389.2 million

    TTM: trailing 12 months

    Aerovate Therapeutics share dividends

    We're not expecting Aerovate Therapeutics to pay a dividend over the next 12 months.

    Aerovate Therapeutics overview

    Aerovate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. .

    Frequently asked questions

    What percentage of Aerovate Therapeutics is owned by insiders or institutions?
    Currently 0.007% of Aerovate Therapeutics shares are held by insiders and 105.043% by institutions.
    How many people work for Aerovate Therapeutics?
    Latest data suggests 25 work at Aerovate Therapeutics.
    When does the fiscal year end for Aerovate Therapeutics?
    Aerovate Therapeutics's fiscal year ends in December.
    Where is Aerovate Therapeutics based?
    Aerovate Therapeutics's address is: 930 Winter Street, Waltham, MA, United States, 02116
    What is Aerovate Therapeutics's ISIN number?
    Aerovate Therapeutics's international securities identification number is: US0080641071

    More guides on Finder

    Ask an Expert

    You are about to post a question on

    • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
    • is a financial comparison and information service, not a bank or product provider
    • We cannot provide you with personal advice or recommendations
    • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

    Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site